TickerFacts.

Inhibikase Therapeutics, Inc. (IKT): Capital Expenditures

Annual figures by period end, from SEC filings.

$13.4K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-62.0%
3-year compound annual growth
$243.3K2021-12-31: $02022-12-31: $243.3K2023-12-31: $14.2K2024-12-31: $02025-12-31: $13.4K$13.4K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$13.4Kn/a2026-03-26, From 2025-01-01
2024-12-31$0-100.0%2026-03-26, From 2024-01-01
2023-12-31$14.2K-94.1%2025-03-27, From 2023-01-01
2022-12-31$243.3Kn/a2024-03-27, From 2022-01-01
2021-12-31$0n/a2023-03-31, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Inhibikase Therapeutics, Inc. (IKT)2025-12-31$13.4Kn/a
Vaxart, Inc. (VXRT)2025-12-31$145.0K-73.8%
Editas Medicine, Inc. (EDIT)2025-12-31$607.0K-93.1%
Caribou Biosciences, Inc. (CRBU)2025-12-31$1.36M-72.2%
SAB Biotherapeutics, Inc. (SABS)2025-12-31$933.2K+176.7%
Aura Biosciences, Inc. (AURA)2025-12-31$447.0K-64.3%
Cabaletta Bio, Inc. (CABA)2025-12-31$1.23M-44.4%
Instil Bio, Inc. (TIL)2024-12-31$0-100.0%
Protara Therapeutics, Inc. (TARA)2025-12-31$94.0K+49.2%

Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗